Latest database descriptions

assess the current prevalence of addictive comorbidities in opioid-dependent subjects who have been receiving opioid substitution therapy (OST) for at least 6 months.

To continuously gather the most detailed information possible on all rare peritoneal cancers occurring in the national population.
To perform a situational analysis on treatment involving these patients and to formulate a research hypothesis on the effectiveness and tolerance to different treatments.

- Maintain and develop the national cohort of MS patients (currently more than 40,000 patients) registered at the EDMUS format (database that can be used as an electronic medical record, specifically designed to process the data of MS patients) and enrich the clinical data currently available with biological samples, MRI data and socio-economic data.
- Provide a continuously updated "photograph" of MS in France, thus allowing a better understanding of the personal, professional and social consequences of the disease, and of the effect of disease modifying treatments (DMTs) in MS care in France. It is ideally suited for nationwide epidemiological studies on MS.
- Maintain and develop existing nested cohorts ("historical" Lyon cohort on the natural history of MS, KIDMUS cohort on MS with childhood onset, TYSEDMUS cohort on patients treated with Tysabri, etc.) and implement new ones, addressing specific issues such as pharmaco-epidemiology of recently introduced DMTs and their cost effectiveness.
To develop the new OFSEP-HD cohort

The main objective is to estimate the overall survival at 24 months of patients with metastatic renal cancer, treated by first line antiangiogenic agents in real-life and investigate (for products for which sufficient data have been collected) if this differs from that reported in pivotal clinical trials that contributed to market authorisation.